Wang Tim T, Hao Jessica, Lee Cameron C, Valerio Danielle DeNufrio, Dalvi Netrali, Keith David A
Resident, Oral & Maxillofacial Surgery, Massachusetts General Hospital and Clinical Fellow, Harvard School of Dental Medicine, Boston, MA.
DMD Candidate, University of Pennsylvania School of Dental Medicine, Philadelphia, PA.
J Oral Maxillofac Surg. 2025 Apr;83(4):407-413. doi: 10.1016/j.joms.2024.12.009. Epub 2024 Dec 25.
Many oral and maxillofacial surgery patients are young, healthy adults who are opioid-naïve. Over-prescribing opioids increases the risk of subsequent misuse and diversion.
The purpose of this study was to measure and compare opioid prescriptions to opioid naïve and nonnaïve patients by oral and maxillofacial surgeons in Massachusetts from 2012 to 2022.
STUDY DESIGN, SETTING, SAMPLE: This retrospective cohort study used the Massachusetts Prescription Monitoring Program database to identify Schedule II and III opioid prescriptions by providers with specialty of oral and maxillofacial surgery from 2012 to 2022.
PREDICTOR/EXPOSURE/INDEPENDENT VARIABLE: The predictor variable is opioid exposure coded as opioid naïve (yes/no). Opioid-naïve status was defined as not having filled an opioid prescription in the prior 12 months.
The main outcome variable was the quantity of opioid prescribed by oral and maxillofacial surgeons measured using morphine milligram equivalent (MME) per prescription. The secondary outcome was days' supply prescribed.
Covariates of the study included patient age and sex.
Descriptive statistics and weighted linear regressions were used to analyze differences in MME per prescription and days's supply per prescription to opioid-naïve and nonnaive patients each year and throughout the study period. P < .05 was considered statistically significant.
The data included a total of 866,539 prescriptions to 679,616 opioid-naïve patients and 186,923 nonnaïve patients from 2012 to 2022. Compared to nonnaïve patients, the opioid-naïve cohort had a slightly higher proportion of females (P ≤ .01 except for 2020) and were significantly younger (35.9 vs 47.6 yrs, P ≤ .01 for all years). For every study year, there was no statistically significant difference in mean MME per prescription or days' supply per prescription between opioid-naïve and nonnaïve patients (P > .05 in all years for both variables). MME per prescription (β = -7.22, 95% CI: -7.65, -6.80; R = 0.79) and days' supply per prescription (β = -0.11, 95% CI: -0.11, -0.10; R = 0.78) decreased at a similar rate throughout the study period for both opioid-naïve and nonnaïve patients.
Oral and maxillofacial surgeons in Massachusetts predominantly prescribed opioids to opioid-naïve patients. The quantity and duration of initial prescriptions to opioid-naïve and nonnaïve patients were similar, yet both steadily decreasing, throughout the study period. These trends are encouraging in the context of recent responsible opioid prescribing policy interventions in Massachusetts.
许多口腔颌面外科手术患者是年轻、健康且未使用过阿片类药物的成年人。阿片类药物处方过量会增加后续滥用和转移的风险。
本研究的目的是测量并比较2012年至2022年马萨诸塞州口腔颌面外科医生给未使用过阿片类药物的患者和使用过阿片类药物的患者开具的阿片类药物处方。
研究设计、设置、样本:这项回顾性队列研究使用马萨诸塞州处方监测计划数据库,以识别2012年至2022年期间口腔颌面外科专业医生开具的II类和III类阿片类药物处方。
预测因素/暴露因素/独立变量:预测变量是阿片类药物暴露情况,编码为未使用过阿片类药物(是/否)。未使用过阿片类药物的状态定义为在过去12个月内未开具过阿片类药物处方。
主要结局变量是口腔颌面外科医生开具的阿片类药物数量,以每张处方的吗啡毫克当量(MME)来衡量。次要结局是开具的用药天数。
研究的协变量包括患者的年龄和性别。
使用描述性统计和加权线性回归分析每年以及整个研究期间未使用过阿片类药物的患者和使用过阿片类药物的患者每张处方的MME以及每张处方的用药天数的差异。P <.05被认为具有统计学意义。
数据包括2012年至2022年期间给679,616名未使用过阿片类药物的患者和186,923名使用过阿片类药物的患者开具的总共866,539张处方。与使用过阿片类药物的患者相比,未使用过阿片类药物的队列中女性比例略高(2020年除外,P≤.01),且明显更年轻(35.9岁对47.6岁,所有年份P≤.01)。在每个研究年份,未使用过阿片类药物的患者和使用过阿片类药物的患者每张处方的平均MME或每张处方的用药天数均无统计学显著差异(两个变量在所有年份P均>.05)。在整个研究期间,未使用过阿片类药物的患者和使用过阿片类药物的患者每张处方的MME(β = -7.22,95% CI:-7.65,-6.80;R = 0.79)和每张处方的用药天数(β = -0.11,95% CI:-0.11,-0.10;R = 0.78)以相似的速率下降。
马萨诸塞州的口腔颌面外科医生主要给未使用过阿片类药物的患者开具阿片类药物。在整个研究期间,给未使用过阿片类药物的患者和使用过阿片类药物的患者开具的初始处方的数量和时长相似,但都在稳步下降。在马萨诸塞州近期实施的负责任的阿片类药物处方政策干预背景下,这些趋势令人鼓舞。